Amyn M. Rojiani , MD, PhD

Department of Pathology, Chairman

Office Phone: (706) 721-2923 
Office Address: BF 104 



Chairman of Pathology.

Edgar R. Pund Distinguished Chair of Pathology.

Clinical Service Chief of Pathology.

Appointment Date

May 2010

Appointment Type



M.D., University of Karachi, 1982

PhD., University of Medicine and Dentistry of New Jersey, 1987

Residency & Fellowships

Residency, University of Medicine and Dentistry of New Jersey, 1989 - Anatomic Pathology.

Fellowship, University of British Columbia/Vancouver General Hospital, 1991 - Neuropathology.

Board Certification(s)

Anatomic Pathology / Neuropathology

Major Interests

Research Areas

Resesearch interests inlucude CNS metastasis, matrix metalloproteinases, and vascular targeting agents including combretastatin. Dr. Rojiani's research focusus on vascular changes and inflammation in Alzheimer's disease.

Selected Publications

■  Rice L, Pampo C, Lepler S, Rojiani AM, Siemann DW. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvasc Res. 2011 Jan;81(1):44-51. Epub 2010 Oct 23. PubMed PMID: 20974154; PubMed Central PMCID: PMC3021177.

■  Rojiani MV, Wiranowska M,  Rojiani AM : Matrix Metalloproteases and Their Inhibitors- Friend or Foe: in “ The Tumor Microenvironment.”  Editor: Siemann DW. Wiley and Sons. 2011

■  DeMers N,  Rojiani AM , Brem S, Rojiani MV: Molecular Mechanisms of Metastasis to the CNS in  “Mechanisms Of Carcinogenesis , Vol 2, Ed: D. Coppola; in the series Cancer Growth and Progression, 2 nd  Edition. 2011

■  Rojiani MV, Alidina J, Esposito N, Rojiani AM. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol. 2010 Oct 16;3(8):775-81. PubMed PMID: 21151391; PubMed Central PMCID: PMC2993228.

■  Riddle ND, Gorden L, Rojiani MV, Hakam A, Rojiani AM. CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. Int J Clin Exp Pathol. 2010 Jun 12;3(5):515-21. PubMed PMID: 20606732; PubMed Central PMCID: PMC2897111.

■  Rojiani MV, Siemann DW, Rojiani AM. Cell proliferation index determination by immunohistochemical detection of hCDC47 protein. Appl Immunohistochem Mol Morphol. 2010 May;18(3):278-82. PubMed PMID: 20048674

■  Barami K, Sloan AE, Rojiani A, Schell MJ, Staller A, Brem S. Relationship of gliomas to the ventricular walls. J Clin Neurosci. 2009 Feb;16(2):195-201. Epub 2008 Dec 18. PubMed PMID: 19097905.

■  Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E, Curran W Jr, Mehta MP. The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol. 2008 Sep 25;3:32. PubMed PMID: 18817556; PubMed Central PMCID: PMC2563009.

■  Jain S, Houseknecht K, Rojiani AM, Setzer M, Vrionis FD. Management of nerve sheath tumors arising in the sympathetic chain. Cancer Control. 2008 Oct;15(4):352-7. PubMed PMID: 18813203.

■  Boeras DI, Granic A, Padmanabhan J, Crespo NC, Rojiani AM, Potter H. Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy. Neurobiol Aging. 2008 Mar;29(3):319-28. Epub 2006 Dec 13. PubMed PMID: 17169464;PubMed Central PMCID: PMC2692942.

■  Sterns RH, Silver S, Kleinschmidt-DeMasters BK, Rojiani AM. Current perspectives in the management of hyponatremia: prevention of CPM. Expert Rev Neurother. 2007 Dec;7(12):1791-7. Review. PubMed PMID: 18052771.

■  Strickland-Marmol LB, Khoor A, Livingston SK, Rojiani A. Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med. 2007 Nov;131(11):1686-90. PubMed PMID: 17979487

■  Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh FR, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Jan;39(2):101-7. Epub 2006 Dec 4. Review. Erratum in: Bone Marrow Transplant. 2007 Feb;39(4):253-4. PubMed PMID: 17143300.

■  Rojiani MV and  Rojiani AM : Morphologic Manifestations of Vascular Disrupting Agents in Pre-clinical Models.” In  Vascular Targeting Agents in Oncology  Editor: Siemann DW. Wiley and Sons. 2006

■  Kleinschmidt-DeMasters BK, Filley CM, Rojiani AM. Overlapping features of extrapontine myelinolysis and acquired chronic (non-Wilsonian) hepatocerebral degeneration. Acta Neuropathol. 2006 Nov;112(5):605-16. Epub 2006 Jul 27. PubMed PMID: 16871403.

■  Silver SM, Schroeder BM, Sterns RH, Rojiani AM. Myoinositol administration improves survival and reduces myelinolysis after rapid correction of chronic hyponatremia in rats. J Neuropathol Exp Neurol. 2006 Jan;65(1):37-44. PubMed PMID: 16410747

■  Kleinschmidt-Demasters BK, Rojiani AM, Filley CM. Central and extrapontine myelinolysis: then...and now. J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11.Review. PubMed PMID: 16410743.

■  Wang M, Tihan T, Rojiani AM, Bodhireddy SR, Prayson RA, Iacuone JJ, Alles AJ, Donahue DJ, Hessler RB, Kim JH, Haas M, Rosenblum MK, Burger PC. Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol. 2005 Oct;64(10):875-81. PubMed PMID: 16215459

■  Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol. 2005 Sep;64(9):743-53. Review. PubMed PMID: 16141783.

■  Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3): 846-53. PubMed PMID: 15936569

■  Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004 Dec 8;1(1):24. PubMed PMID: 15588287; PubMed Central PMCID: PMC539292.

■  Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti SM, Mullan M. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 2004;7(1):75-85. PubMed PMID: 15302999

■  Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004 Jul 7;24(27):6144-51. PubMed PMID: 15240806.

■  Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1512-7. PubMed PMID: 12459379

■  Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):164-71. PubMed PMID: 12007956.

■  Rojiani AM, Li L, Rise L, Siemann DW. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol. 2002;41(1):98-105. PubMed PMID: 11990526

■  Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol. 2002;41(1):91-7. PubMed PMID: 11990525.

■  Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer. 2002 May 1;99(1):1-6. PubMed PMID: 11948484

■  Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 2002 Mar 15;22(6):2246-54. PubMed PMID: 11896164.

■  Tan J, Town T, Mori T, Obregon D, Wu Y, DelleDonne A, Rojiani A, Crawford F, Flavell RA, Mullan M. CD40 is expressed and functional on neuronal cells. EMBO J. 2002 Feb 15;21(4):643-52. PubMed PMID: 11847112; PubMed Central PMCID: PMC125862.

■  Bloomston M, Shafii A, Zervos EE, Rojiani A, Rosemurgy AS. MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer. J Surg Res. 2002 Jan;102(1):35-8. PubMed PMID: 11792149


For a complete listing of all publications, see Dr. Rojiani's work at PubMed.